|
stain of diphtheria |
CDC describes diphtheria as "an upper respiratory tract illness characterized by sore throat, low-grade fever, and an adherent membrane of the tonsil(s), pharynx, and/or nose". Diphtheria is a rapidly developing, acute, febrile infection which involves both local and systemic pathology. A local lesion develops in the upper respiratory tract and involves necrotic injury to epithelial cells. As a result of this injury, blood plasma leaks into the area and a fibrin network forms which is interlaced with with rapidly-growing C. diphtheriae cells.
|
|
|
|
|
|
|
|
FDA Talk Paper | First Combination Vaccine Approved to Help Protect Adolescents Against Whooping Cough
|
|
|
|
|
|
ALARACT PDF 21 Jan 06 | ADOPTION OF NEW TETANUS-DIPHTHERIA-ACELLULAR PERTUSSIS (TDAP)
VACCINE
|
|
|
|
|
|
MMQC-06-1289 | SANOFI PASTEUR TEMPORARY SHORTAGE OF ADACELĀ® VACCINE / UPDATED INFORMATION BULLETIN
|
|
|
MMQC-06-1235 | SANOFI PASTEUR / DECAVACĀ® VACCINE (TETANUS & DIPHTHERIA TOXOID) / AMERISOURCE BERGEN VOLUNTARY RECALL
|
|
|
MMQC-06-1219 | SANOFI PASTEUR DECAVAC (DIPHTHERIA TOXOID, ADSORBED / TETANUS TOXOID) / VOLUNTARY RECALL / DSCP 06-124
|
|
|
|
|
|
|